16 / 39
Volume 4
Nano Research & Applications
ISSN: 2471-9838
Page 75
JOINT EVENT
August 16-18, 2018 | Dublin, Ireland
&
12
th
Edition of International Conference on
Nanopharmaceutics and Advanced Drug Delivery
25
th
Nano Congress for
Future Advancements
Nano Congress 2018
&
Nano Drug Delivery 2018
August 16-18, 2018
Nano Res Appl 2018, Volume 4
DOI: 10.21767/2471-9838-C3-015
Development of novel versatile theranostic platforms based on titanate nanotubes: Newsafe nanovectors
for drugs, plasmid DNA and imaging probes
Nadine Millot
1
, Fadoua Sallem
1
, Alexis Loiseau
1
, Anne Laure Papa
2
and
Julien Boudon
1
1
ICB Laboratory UMR 6303 - CNRS, France
2
The George Washington University, USA
T
he concept of nanomaterials that can be designed and administered into the human body to improve health is of great
interest. During the past years there has been an increasing amount of research on the uses of nanomaterials in diverse
areas of biomedical research including biological sensing, labelling, imaging, cell separation and therapy. In this conference,
the first evaluation of titanate nanotubes (TiONts) as potential carriers of therapeutic molecules will be presented. Our research
group has developed TiONts with controlled parameters from a hydrothermal synthesis and explored biomedical applications
over the last decade. These nanotubes are currently elaborated as stable suspensions of nanocarriers by surface chemistry
engineering, they can be used as novel transfection agents for cardiomyocytes and we have shown that TiONts are capable of
increasing the ionizing effect of radiation therapy in the case of glioblastoma. Furthermore, TiONts’ biodistribution has already
been evaluated by SPECT/CT in male Swiss nude mice and TiONts are quickly excreted. More recently we have demonstrated
that TiONts-docetaxel (DTX) nanohybrids are versatile nanocarriers in order to limit the systemic toxicity of taxanes and
to improve the selectivity of radiotherapy (RT). Our strategy is based on the intraprostatic injection of the TiONts-DTX
nanohybrids both in place of brachytherapy and in combination with RT. This is achieved by taking advantage of the TiONts
morphology as well as their radiosensitization effect and by associating them with docetaxel molecules, also recognized for
their potential to radiosensitization. We also grafted the surface of TiONts with gold nanoparticles, for a resulting combined
radiosensitizing effect. Biodistribution kinetics showed that more than 70% of nanohybrids were localized into tumors 96 hours
after injection. Mice receiving nanohybrid-RT exhibited a significant tumor growth delay compared to mice receiving free
DTX-RT. The elaboration of nanohybrid materials, intended for drug delivery systems, based on TiONts coated with chitosan
polymer has also been evaluated. Such nanotubes are combined with transresveratrol derivatives for their anti-oxidizing and
antitumor effects.
nadine.millot@u-bourgogne.fr